Curis AI Stock Analysis
Want to see CRIS full AI Analyst Report?
Curis (CRIS) AI Stock Analysis
Curis
(NASDAQ:CRIS)
The score is held down primarily by weak financial performance (sharp TTM revenue decline, large ongoing losses, and significant cash burn) and a weak longer-term technical trend (price below the 50/100/200-day averages with negative MACD). Offsetting some of this is a more constructive earnings-call outlook driven by encouraging PCNSL response data and stated progress toward enrollment and a potential accelerated approval path, though liquidity and listing-risk events remain material concerns.
Curis (CRIS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.20M
- Dividend Yield
- ―
- Average Volume (3M)
- 4.18M
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 2.22
- Revenue Growth
- -90.23%
- EPS Growth
- 91.34%
- Country
- US
- Employees
- 22
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Curis Business Overview & Revenue Model
Company Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...
Curis Earnings Call Summary
The call was predominantly optimistic, driven by strong and consistent PCNSL response data, progress toward full enrollment and potential accelerated approval submissions, the upcoming CLL data readout, and a stated cash runway into 2027. The main negatives were the higher year-to-date net loss, limited cash balance, choppy enrollment in the ultra-orphan PCNSL indication, and the fact that CLL efficacy data remain pending.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Curis expects to be fully enrolled in the PCNSL registrational study by the end of 2027, with 10 to 15 more patients needed, and, assuming that happens, anticipates filing for NDA for the accelerated approval in 2028 after following patients for probably 6 months from last patient in; responses are typically obtained in the first few cycles, the hurdle is generally a 20% ORR, and only a couple of responses are needed in order to hit the hurdle. In CLL, the company remains on track to report initial clinical data by year-end, with 12 patients on study across 11 clinical sites, including patients on drug for 3 or 4 cycles and potentially some patients with data for only a cycle or 2. Based on its current operating plan, Curis believes its existing cash and cash equivalents, along with the financing from October, should enable it to fund existing operations into '27.
Curis Financial Statement Overview
Summary
Income statement and cash flow are weak: TTM revenue fell sharply to about $1.1M with large ongoing losses (TTM EBIT about -$37.8M) and significant cash burn (TTM OCF/FCF about -$30.8M). The balance sheet shows modest leverage (debt-to-equity ~0.29, total debt ~$0.7M), but equity has compressed materially over time, reducing financial flexibility.
Income Statement
18Very NegativeBalance Sheet
44NeutralCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.14M | 9.44M | 10.91M | 10.02M | 10.16M | 10.65M |
| Gross Profit | 1.11M | 9.40M | 10.81M | 9.81M | 9.90M | 10.12M |
| EBITDA | -22.90M | -5.23M | -42.57M | -45.14M | -51.67M | -40.81M |
| Net Income | -21.54M | -7.58M | -43.39M | -47.41M | -56.67M | -45.44M |
Balance Sheet | ||||||
| Total Assets | 18.80M | 19.97M | 41.27M | 77.28M | 108.85M | 162.30M |
| Cash, Cash Equivalents and Short-Term Investments | 5.01M | 5.06M | 20.00M | 56.33M | 85.62M | 115.88M |
| Total Debt | 740.00K | 1.62M | 2.95M | 2.79M | 3.94M | 5.04M |
| Total Liabilities | 16.25M | 14.50M | 47.26M | 57.61M | 62.30M | 71.59M |
| Stockholders Equity | 2.55M | 5.46M | -6.00M | 19.67M | 46.55M | 90.71M |
Cash Flow | ||||||
| Free Cash Flow | -30.77M | -27.20M | -39.56M | -38.43M | -54.75M | -37.62M |
| Operating Cash Flow | -30.77M | -27.20M | -39.56M | -38.43M | -54.34M | -37.62M |
| Investing Cash Flow | 2.50M | 2.50M | 29.44M | 37.79M | 33.02M | -47.90M |
| Financing Cash Flow | 24.23M | 9.77M | 3.44M | 7.58M | 867.00K | -4.17M |
Curis Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CRIS, the sentiment is Neutral. The current price of 0.47 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.72, and below the 200-day MA of 7.89, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.61 is Neutral, neither overbought nor oversold. The STOCH value of 18.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CRIS.
Curis Risk Analysis
Curis disclosed 60 risk factors in its most recent earnings report. Curis reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksCuris Peers Comparison
Overall Rating
ATNM59Neutral
CLRB45Neutral
CRIS45Neutral
CNSP41Neutral
NCNA38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 59Neutral | $33.96M | 3.27 | 65.18% | ― | 38788.89% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 45Neutral | $9.24M | -0.24 | -154.53% | ― | ― | 66.06% | |
| 45Neutral | $5.84M | -0.10 | -339.08% | ― | -90.23% | 91.34% | |
| 41Neutral | $6.12M | -0.24 | -166.03% | ― | ― | 68.89% | |
| 38Underperform | $4.29M | -0.20 | -51.04% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CRIS | Curis Inc. | 0.47 | -22.93 | -98.00% | |
| ATNM | Actinium Pharmaceuticals | 1.07 | -0.26 | -19.55% | |
| CLRB | Cellectar Biosciences Inc | 0.88 | -1.98 | -69.16% | |
| NCNA | Nucana Plc | 0.72 | -2.78 | -79.49% | |
| CNSP | Cns Pharmaceuticals, Inc. | 3.92 | -2.99 | -43.26% |
Curis Corporate Events
Curis Faces Nasdaq Delisting Risk After Bid-Price Deficiency
NegativeOn November 2, 2026, Curis, Inc. received a Nasdaq delisting determination after its common stock’s bid price closed below the $1 minimum for 30 consecutive business days. Because Curis had completed a 1-for-20 reverse stock split on July 6, 2026, it...
Curis Secures PIPE Financing Through Securities Purchase Agreement
PositiveOn October 16, 2026, Curis entered into a private securities purchase agreement with institutional investors to sell 16,666,680 shares of common stock or pre-funded warrants, plus matching common warrants, at an effective combined price of $0.51 per...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 19, 2026
